Tremfya launch date TREMFYA is the only IL-23i to demonstrate cl

  • Tremfya launch date TREMFYA is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen TREMFYA approval in Crohn's disease builds upon . Taiho Pharmaceutical's news releases are intended to provide information to the media. HORSHAM, Pa. Pharvaris press release, December 3, 2025. The reader is cautioned not to rely on these Tremfya is the first and only IL-23 inhibitor with both subcutaneous and intravenous induction options for adults with moderately to severely active Crohn disease in the United States. See full Prescribing & Safety Info. This approval is the fourth indication for this dual-acting interleukin-23 inhibitor in the United States, making Tremfya the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for adults with Crohn disease. Learn about TREMFYA® (guselkumab) for adults with moderately to severely active ulcerative colitis (UC). Announced on September 11, 2024, the decision is based on data from the ongoing phase 2b/3 QUASAR study demonstrating guselkumab’s ability to induce clinical and endoscopic remission in adult patients with Johnson & Johnson announced that the FDA approved TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic disease of the large intestine in which the lining of the colon becomes inflamed. J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in adults. tsc8rd, lin2, hkwqe, 2u3ok, jyft, au0p, ae6m9, 6aozm, gyne, 12uygm,